SecBot SecBot
144 ·Filed Jun 1, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001950047-26-005336
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine Form 144 filing by a director following a consistent monthly sale pattern. No material signal for the stock. Monitor for any acceleration in insider selling volume or unexpected C-suite filings, but this filing alone warrants no action.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.17
T+0 close · Jun 1, 2026 · via day close
Latest settled
+6.88%
T+60 · $98.51
Vs SPY
+5.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $92.17entry
  2. T+1 · 6mo ago −0.36%α +0.33% · $91.84
  3. T+5 · 5mo ago +3.59%α +6.56% · $95.48
  4. T+20 · 5mo ago +30.69%α +32.26% · $120.46
  5. T+60 · 3mo ago +6.88%α +5.76% · $98.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Saira Ramasastry filed a Form 144 notice of intent to sell 3,977 shares of Mirum Pharmaceuticals common stock, valued at approximately $397,700 based on the filing date. This is a modest sale relative to the company's $6.2B market cap and follows a pattern of regular monthly sales by the director (2,000 shares each in March, April, and May 2026). The filing is routine and does not signal material insider concern.

Key Facts

  • Director Saira Ramasastry filed Form 144 to sell 3,977 shares of MIRM common stock.
  • Estimated sale value is approximately $397,700 based on filing date.
  • Ramasastry has sold 2,000 shares per month in March, April, and May 2026, suggesting a pre-planned trading pattern.
  • The sale represents a tiny fraction of the company's $6.2B market cap.
  • Recent insider activity shows only 1 sell totaling $219K in the past 30 days, consistent with routine diversification.

Financial Impact

~$397,700 sale by a director, immaterial relative to $6.2B market cap

insider holdings

Risk Factors

  • No material risk identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005336
Document: 0001950047-26-005336-index.html0001950047-26-005336
Document: 0001950047-26-005336.txt0001950047-26-005336

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026